Validation Data Gallery
Filter:
Tested Applications
| Positive WB detected in | SH-SY5Y cells, HeLa cells, mouse testis tissue |
| Positive FC detected in | SH-SY5Y cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:1000-1:4000 |
| Flow Cytometry (FC) | FC : 0.40 ug per 10^6 cells in a 100 µl suspension |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Published Applications
| KD/KO | See 1 publications below |
| WB | See 3 publications below |
| FC | See 1 publications below |
Product Information
22192-1-AP targets CHRNB4 in WB, ELISA applications and shows reactivity with human, mouse samples.
| Tested Reactivity | human, mouse |
| Cited Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen | CHRNB4 fusion protein Ag16767 相同性解析による交差性が予測される生物種 |
| Full Name | cholinergic receptor, nicotinic, beta 4 |
| Calculated molecular weight | 498 aa, 56 kDa |
| Observed molecular weight | 48-60 kDa |
| GenBank accession number | BC096080 |
| Gene Symbol | CHRNB4 |
| Gene ID (NCBI) | 1143 |
| RRID | AB_11232227 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | P30926 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Protocols
| Product Specific Protocols | |
|---|---|
| WB protocol for CHRNB4 antibody 22192-1-AP | Download protocol |
| FC protocol for CHRNB4 antibody 22192-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
| Species | Application | Title |
|---|---|---|
Mar Drugs Differential Expression of Nicotine Acetylcholine Receptors Associates with Human Breast Cancer and Mediates Antitumor Activity of αO-Conotoxin GeXIVA. | ||
Eur J Pharmacol Identification of nicotinic acetylcholine receptor subunits in different lung cancer cell lines and the inhibitory effect of alpha-conotoxin TxID on lung cancer cell growth. | ||
Cancers (Basel) An Integrated Genomic Strategy to Identify CHRNB4 as a Diagnostic/Prognostic Biomarker for Targeted Therapy in Head and Neck Cancer.
| ||
Mar Drugs Cervical Cancer Correlates with the Differential Expression of Nicotinic Acetylcholine Receptors and Reveals Therapeutic Targets. |